Think of it as a music playlist to suit your mood or changes in the patient’s condition.Ībbott has devoted considerable resources to positioning itself as the patient-centric solution for neuromodulation. This is especially useful for different activities or environmental changes, such as time of day. Complex adjustments will still be done by a physician, but multiple programming options will be available to the patient through the app. The new app will allow patients to control what program they are on and will provide the ability to adjust settings. The smartphone app approach is a part of Abbott’s NeuroSphere Digital Care platform that was launched earlier this year. Integration with Android and other digital platforms such as Alexa are also in development. The new app is currently approved only for iOS devices approximately 65 percent of patients implanted with Abbott stimulators already use smartphones. Moving to a ubiquitous platform such as a smartphone also allows patients who are sensitive or feel a stigma around using the separate controller in public to discretely adjust their therapies. Patients will no longer have to carry, charge, and manage a separate controller. The new app is compatible with the company’s Infinity DBS system, Proclaim XR SCS system, and Proclaim DRG neurostimulation system. At NANS 2020, the company reported that mySCS improved trial success rate from 85 to 91 percent.Įarlier this month, Abbott announced that the FDA approved their iOS patient controller app to allow patients and physicians the ability to customize treatment remotely and without having to carry an additional device dedicated to managing a patient’s implanted device. The app produces a detailed trial summary report that helps increase the chances of a successful permanent implant. Last year, Boston Scientific introduced the mySCS app, a patient education tool that also allows patients to provide feedback to clinicians during a stimulation trial. The apps also offer clinicians an increased opportunity for remote medicine at a time when the coronavirus pandemic has made office visits less tenable. Vendors of implanted neuromodulation systems have turned increasingly to new smartphone apps to enable patients to exert more control over their therapeutic regimens. Vendors Give Patients Control with Smartphone Appsīy Jo Jo Platt, contributing editor and James Cavuoto, editor
0 Comments
Leave a Reply. |